Shares of Zogenix (NASDAQ:ZGNX) have earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $53.00.
A number of research firms have weighed in on ZGNX. Mizuho reissued a “buy” rating and set a $51.00 target price on shares of Zogenix in a research report on Thursday, May 10th. ValuEngine raised shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research report on Thursday, March 15th. BidaskClub raised shares of Zogenix from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, Leerink Swann reissued an “outperform” rating on shares of Zogenix in a research report on Sunday, March 4th.
Zogenix stock opened at $39.95 on Tuesday. Zogenix has a 1 year low of $39.05 and a 1 year high of $39.50. The company has a market capitalization of $1.40 billion, a PE ratio of -9.94 and a beta of 1.70.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.13). During the same quarter in the prior year, the business earned ($0.86) earnings per share. analysts expect that Zogenix will post -3.89 EPS for the current fiscal year.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of ZGNX. Creative Planning bought a new position in shares of Zogenix during the 4th quarter worth approximately $1,008,000. Chicago Equity Partners LLC bought a new position in shares of Zogenix during the 4th quarter worth approximately $1,241,000. Mutual of America Capital Management LLC bought a new position in shares of Zogenix during the 4th quarter worth approximately $1,223,000. Teacher Retirement System of Texas bought a new position in shares of Zogenix during the 4th quarter worth approximately $409,000. Finally, California Public Employees Retirement System boosted its holdings in shares of Zogenix by 2.4% during the 4th quarter. California Public Employees Retirement System now owns 59,150 shares of the company’s stock worth $2,369,000 after buying an additional 1,400 shares in the last quarter.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.